Cosmos Health Inc. (COSM): Nasdaq/NYSE listing notice — Cosmos Health receives Nasdaq bid-price deficiency notice; 180 days to cure

Cosmos Health Inc.

Nasdaq notified company on March 20, 2024 that bid price closed below $1.00 for 30 consecutive days.
Company has 180 calendar days (to ~Sept 16, 2024) to regain compliance by having bid price ≥ $1.00 for 10 consecutive days.
If unable to comply, company intends to effect a reverse stock split to regain compliance.
A deficiency indicator will be displayed on Nasdaq for the company's common stock (COSM).
The notice does not affect listing immediately; trading continues normally during cure period.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cosmos Health Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 20, 2024, Cosmos Health Inc. (the “Company”) received a non-compliance letter from Nasdaq for its failure to maintain a minimum bid price of $1.00 per share for thirty (30) consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2). The Company has one hundred eighty (180) calendar days from March 20, 2024 to regain compliance by the closing bid price of the Company’s common stock being at least $1.00 per share for ten (10) consecutive business days. In the event the Company cannot otherwise regain compliance with the listing rule, it intends to effect a reverse stock sp

View on SEC.gov

Browse all listing & compliance notices →

Cosmos Health Inc. filing history →

Source: SEC EDGAR

accession 0001477932-24-001429

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.